$25.00
4.34% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
BMG5269C1010
Symbol
KNSA
Sector
Industry

Kiniksa Pharmaceuticals Ltd. Class A Stock price

$25.00
-2.06 7.61% 1M
+5.01 25.06% 6M
+7.46 42.53% YTD
+7.39 41.96% 1Y
+12.90 106.61% 3Y
+16.28 186.70% 5Y
+5.53 28.40% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+1.04 4.34%
ISIN
BMG5269C1010
Symbol
KNSA
Sector
Industry

Key metrics

Market capitalization $1.71b
Enterprise Value $1.50b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 49.48
EV/Sales (TTM) EV/Sales 4.42
P/S ratio (TTM) P/S ratio 5.04
P/B ratio (TTM) P/B ratio 3.91
Revenue growth (TTM) Revenue growth 20.69%
Revenue (TTM) Revenue $338.93m
EBIT (operating result TTM) EBIT $-27.51m
Free Cash Flow (TTM) Free Cash Flow $30.31m
Cash position $218.76m
EPS (TTM) EPS $-0.16
P/E forward negative
P/S forward 4.05
EV/Sales forward 3.56
Short interest 14.52%
Show more

Is Kiniksa Pharmaceuticals Ltd. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Kiniksa Pharmaceuticals Ltd. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

Buy
100%

Financial data from Kiniksa Pharmaceuticals Ltd. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
339 339
21% 21%
100%
- Direct Costs 128 128
91% 91%
38%
211 211
1% 1%
62%
- Selling and Administrative Expenses 149 149
45% 45%
44%
- Research and Development Expense 87 87
26% 26%
26%
-25 -25
160% 160%
-7%
- Depreciation and Amortization 2.13 2.13
50% 50%
1%
EBIT (Operating Income) EBIT -28 -28
172% 172%
-8%
Net Profit -10 -10
104% 104%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Kiniksa Pharmaceuticals Ltd. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kiniksa Pharmaceuticals Ltd. Class A Stock News

Neutral
GlobeNewsWire
about one month ago
LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 8:00 a.m. Eastern Time.
Positive
Seeking Alpha
2 months ago
Kiniksa Pharmaceuticals surged after the company reported strong second quarter results and increased the full year net sales guidance range for Arcalyst. The strong performance is driven by increased demand following the recent sales force expansion. The improved outlook for Arcalyst warrants an increase in the valuation range.
Neutral
Seeking Alpha
2 months ago
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q2 2024 Earnings Conference Call July 23, 2024 8:30 AM ET Company Participants Rachel Frank – Head of Investor Relations Sanj K. Patel – Chief Executive Officer Ross Moat – Chief Commercial Officer Mark Ragosa – Chief Financial Officer John Paolini – Chief Medical Officer Conference Call Participants Anupam Rama – JPMorgan Eva Fortea-Ver...
More Kiniksa Pharmaceuticals Ltd. Class A News

Company Profile

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Sanj Patel
Employees 297
Founded 2015
Website www.kiniksa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today